Showing: all postings
|Scientist LCMS (https://www.adimab.com/)|
Adimab is seeking a skilled biochemist to join our Protein Analytics team. This person will work in a small team setting to support Adimab’s novel antibody discovery, maturation, and production platform.
-Develop and execute LCMS-related assays to characterize therapeutic antibodies, investigate PTMs, identify epitopes, and survey chemical liabilities
Needed upon hire
-M.S. in biochemistry, analytical chemistry or a related field; industry experience preferred
Come join us!
As a profitable privately-held biotech company, we take a long-term view on value creation and make substantial investments in technology development, research, and our people. We proudly promote meritocracy and reward employees who are productive, use their resources wisely, and make meaningful contributions to the team. We offer individually tailored compensation packages comprised of a competitive salary, meaningful equity, a 2:1 401(k) match, and comprehensive health care benefits.
Located in New Hampshire’s beautiful Upper Connecticut River Valley, we are minutes from Dartmouth College, the Geisel School of Medicine, the Thayer School of Engineering, the Tuck School of Business, and the Dartmouth Hitchcock Medical Center. We are fortunate to be situated in an area that is renowned for its premier skiing, hiking, and biking.
|Post-doctoral research position in functional cancer proteomics|
Functional Cancer Proteomics
We are a group of biochemists, biologists and physicians in the Molecular Pharmacology Program at the Sloan Kettering Institute in New York City, USA. We carry out research in cancer biology, and our current work is focused on the phenomenon of cellular plasticity, as it relates both to the fundamental mechanisms of cancer pathogenesis and emerging rational therapies.
In particular, we are studying the biology of refractory leukemias and solid tumors, and we are interested in understanding the principles of disorganization of their genomes and proteomes, and determining the molecular mechanisms of response and adaptation of tumor cells to targeted therapies.
To answer these questions, we are developing new approaches, based on quantitative mass spectrometry and functional proteomics, to decipher the mechanisms of cancer cell signaling and develop new therapeutics.
Forward Proteomic Screens for Cancer Therapeutics and Macromolecular Delivery. Using recently developed methods for quantitative proteomics and peptide barcoding (Egloff et al, Nature Methods 2019, PMID: 31113958), we’ve developed a new platform for high-throughput design and screening of macromolecular cell penetration and delivery reagents. This is a transformative technology that enables the generation of new classes of drugs to modulate specific protein-protein interactions, which we’ve recently applied for targeted leukemia therapy (Ramaswamy et al, Nature Communications 2018, PMID 29317678). Current efforts are focused on applying this technology for protein engineering and development of new peptide conjugates for cancer and gene therapy.
Quantitative Cell Proteomics Atlas (http://qcpa.mskcc.org). Using developed methods for ultra-sensitive quantitative proteomics (Cifani & Kentsis, MCP 2017, PMID 28821601), we’ve developed an atlas of targeted mass spectrometry assays to profile biochemical signaling at the pathway scale in normal and cancer cells. Current efforts are focused on developing high-throughput and genome-scale methods. This work aims to define systems-level mechanisms of aberrant signaling in cancer cells, as well as fundamental cell biological processes of signaling adaptation, feedback and integration.
If you are a recent PhD graduate with interest in the above areas and experience with nanoscale liquid chromatography, electrospray ionization, high-resolution mass spectrometry or protein engineering and chemistry, please contact Alex Kentsis at http://alexkentsis.net/ or firstname.lastname@example.org
|Postdoc in Targeted Proteomics, Aarhus University, Aarhus|
The Department of Biomedicine at Faculty of Health at Aarhus University invites applications for a three-year position as Postdoc in the field of Targeted Proteomics as per 1 December 2019 or as soon as possible thereafter. The position is a fixed-term full-time position.
We offer a vibrant international research environment where English is the preferred language in the laboratory, at meetings and at seminars. The Department employs some 450 people and covers a range of research areas within Biomedicine. We contribute to the Bachelor’s degree programs in medicine, molecular medicine, odontology and the Master’s degree programs in biomedical engineering and medical chemistry. Our infrastructure is well developed with modern laboratories, core and animal facilities. You will work either in the brand new ‘Skou Building’ or similar as we are in the process of modernizing our old facilities. You can read more about the department here (https://biomed.au.dk/en/) and about the faculty here (http://health.au.dk/en/).
About the research project
Your job responsibilities
Your main tasks will consist of:
Independent research of high international quality, including publication.
You will report to Professor Bent Honoré and be supervised by him.
MSc/PhD in human biology, molecular biology, molecular medicine or similar.
For further information please see: http://health.au.dk/om-health/ledige-stillinger/job/postdoc-in-targeted-proteomics/
If you have any questions about the position, please contact Professor Bent Honoré at email@example.com. The application must be submitted via Aarhus University’s recruitment system at the latest on the 10th of October 2019, which can be accessed under the job advertisement on Aarhus University's website.
|Translational Research Scientist (with Proteomic Mass Spec expertise)|
#1! That’s the ranking that Fast Company gave Novartis in their 2018 list of ‘The World’s Most Innovative Companies’. The Novartis Institutes for BioMedical Research (NIBR) is the innovation engine of Novartis. We collaborate across scientific and organization boundaries, focusing on powerful new technologies that have the potential to help produce therapeutic breakthroughs from patients.
We seek a creative and collaborative scientist to join the Exploratory Translational Profiling group in Disease Area X and contribute to advancing novel therapeutics by enabling the discovery and validation of novel biomarkers. In this role, you will focus on discovery and targeted proteomics of clinical samples from well-designed disease cohorts, applying competitive edge mass spectrometry and aptamer/antibody-based approaches.
Your responsibilities will include:
• Developing and employing novel approaches to identify, profile and quantify biomarkers in clinical samples to support translational research across multiple therapeutic areas of unmet medical need, including hepatology, nephrology and benign hematology
• BS with +7 years experience or MS with +3 years experience in relevant scientific area.
Additional desirable attributes include, but are not limited to:
• Translational research and industry working experience, including the handling of clinical samples and data
Why consider Novartis?
750 million. That’s how many lives our products touch. And while we’re proud of that fact, in this world of digital and technological transformation, we must also ask ourselves this: how can we continue to improve and extend even more people’s lives?
We believe the answers are found when curious, courageous and collaborative people like you are brought together in an inspiring environment. Where you’re given opportunities to explore the power of digital and data. Where you’re empowered to risk failure by taking smart risks, and where you’re surrounded by people who share your determination to tackle the world’s toughest medical challenges.
We are Novartis. Join us and help us reimagine medicine.
You can apply using the following link: Job ID 276154BR
|Postdoctoral Scholar - Proteomics|
Dr. Lewis‘ team employs state-of-the-art mass spectrometry to investigate the metabolic dynamics of opportunistic pathogens, including Pseudomonas aeruginosa and Staphylococcus aureus, and is working to develop new approaches to detect and control human infections.
The Lewis laboratory is looking for a postdoctoral fellow to aid in developing a large precision medicine project related to microbial proteomics. This position will be a critical part of an interdisciplinary team working to integrate genomics, proteomics, metabolomics, and clinical data to help develop a new approach to infection management.
We are a large, interdisciplinary research group including proteomics, metabolomics, engineering and computer science as well as several Mass Specs for your need.
Check out our posting at https://asms-jobs.careerwebsite.com/job/postdoctoral-scholar-proteomics/41095545/
|Assoc.Scientist - Proteomics/Immunopeptidomics|
Regeneron is looking for a highly motivated Associate Scientist who will leverage our state-of-the-art facilities and technology to perform qualitative and quantitative mass spectrometry experiments focusing on autoimmune, infectious disease and oncology targets. The successful candidate’s primary responsibility will be to utilize the latest mass spectrometry techniques for the discovery and validation of novel viral- and cancer-specific antigens from human tissues and cell lines as well as to develop innovative techniques and investigate new technologies to enhance our target discovery efforts.
Please apply using the link below